University of Kentucky Markey Cancer Center Oncologist Dr. Edward Romond spent his career at UK treating and studying breast cancer, even leading major Phase 3 clinical trials on the breast cancer drug trastuzumab in the early 2000s. Commonly known as Herceptin, this drug became a standard of care for patients with HER2-positive breast cancer.

On the first of May, 2015, Angelique Bell waited in a hair salon, reading the weekend section of the newspaper. She noticed an ad for a health research study that needed participants who had risk factors for diabetes. Since she met the criteria and had some time to pass, she decided to call about the study right then, from the salon chair. It was her 45th birthday.

UK HealthCare's Gill Heart Institute and The Christ Hospital in Cincinnati have partnered to test a new treatment for adults with congenital heart disease.

The COMPASSION Trial will test the efficacy of the Sapien 3 valve as a replacement for a diseased pulmonary valve. The Sapien 3 has already been approved for replacement of the aortic valve.

On Dec. 2, a very special group of people gathered to celebrate a very special gift.

The University of Kentucky's Sanders-Brown Center on Aging is participating in a landmark multi-center clinical trial of an experimental drug that has the potential to prevent Alzheimer's disease (AD).

As a reminder, clinical trial F&A rates for industry-funded studies increased effective 7/1/2013. Please be sure to use this rate in study budgets being discussed with sponsors. Information can be found here: http://www.research.uky.edu/ospa/info/clinical_info.html.